Sort
48,018 grants matching “immunotherapy”
Breaking down tumor immune privilege through targeted hypoxia reduction
$472,058Michael A. Curran · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer
$472,040Yonathan Lissanu · University Of Tx Md Anderson Can Ctr · R37 · FY2021 · CA
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer
$472,040Yonathan Lissanu · University Of Tx Md Anderson Can Ctr · R37 · FY2022 · CA
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer
$472,040Yonathan Lissanu · University Of Tx Md Anderson Can Ctr · R37 · FY2020 · CA
Clinical Trials in Mesothelioma
$472,015Daniel Sterman · University Of Pennsylvania · P01 · FY2009 · CA
Mechanisms of increased susceptibility to TB in HIV-Infected individuals
$472,012David H Canaday · Case Western Reserve University · R01 · FY2011 · AI
Targeting Neoantigens in Glioblastoma
$471,961Gavin Peter Dunn · Washington University · R01 · FY2020 · NS
Role of IL-17+ Autoreactive T Cells in Experimental Autoimmune Uveitis (EAU)
$471,955Deming Sun · Doheny Eye Institute · R01 · FY2023 · EY
Role of IL-17+ Autoreactive T Cells in Experimental Autoimmune Uveitis (EAU)
$471,955Deming Sun · Doheny Eye Institute · R01 · FY2020 · EY
Effects of autoantibodies on synaptic transmission in the retina
$471,865Catherine W Morgans · Oregon Health & Science University · R01 · FY2016 · EY
B7-H1/PD-1 modulation in cancer therapy
$471,842Drew M. Pardoll · Johns Hopkins University · R01 · FY2012 · CA
Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC
$471,791Judith A. Varner · University Of California, San Diego · R01 · FY2020 · CA
Non-Human Primate and Imaging Core
$471,691Francois J Villinger · Northwestern University At Chicago · P01 · FY2018 · AI
CD8+ T Cell Immunity to Cytomegalovirus
$471,690Stanley R Riddell · Fred Hutchinson Cancer Research Center · R01 · FY2013 · AI
CEA TARGETED IMMUNOTHERAPEUTICS
$471,632Andrew A. Raubitschek · Beckman Research Institute/City Of Hope · P01 · FY2012 · CA
Development of Allogeneic CAR T Cell Therapy for a Functional Cure of HIV Infection
$471,626Christian L. Boutwell · Massachusetts General Hospital · R01 · FY2024 · AI
Development of Allogeneic CAR T Cell Therapy for a Functional Cure of HIV Infection
$471,626Christian L. Boutwell · Massachusetts General Hospital · R01 · FY2025 · AI
Development of Allogeneic CAR T Cell Therapy for a Functional Cure of HIV Infection
$471,626Todd M Allen · Massachusetts General Hospital · R37 · FY2023 · AI
Molecular and Cellular Mechanisms of Tolerance to Combined Organ and Hematopoietic Cell Transplantation after TLI and ATS/ATG Conditioning
$471,607Edgar G. Engleman · Stanford University · P01 · FY2016 · HL
Molecular basis of glycan recognition by T and B cells
$471,585Luc Teyton · Scripps Research Institute, The · P01 · FY2025 · AI
PATHOGENESIS OF LIVER DISEASE IN HEPATITIS
$471,489Scripps Research Institute · R01 · FY2001 · AI
Peripheral mechanisms of homeostasis and tolerance through skin dendritic cells
$471,480Niroshana Anandasabapathy · Weill Medical Coll Of Cornell Univ · R01 · FY2018 · AR
Project 3: Determination of the minimal MHC-E-restricted SIV epitope targeting required for RhCMV/SIV vaccine-mediated SIV replication arrest efficacy
$471,466Louis J. Picker · Oregon Health & Science University · P01 · FY2023 · AI
Targeting telomerase for melanoma therapeutics
$471,448Emmanuel Skordalakes · Wistar Institute · R01 · FY2018 · CA
Targeting telomerase for melanoma therapeutics
$471,448Emmanuel Skordalakes · Wistar Institute · R01 · FY2020 · CA